Company intelligence / Profile preview

SILTISS

Brive-la-Gaillarde, Nouvelle-Aquitaine, Francepmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

SILTISS develops innovative natural-origin biomaterials for tissue regeneration. Its lead products are bone substitutes intended for orthopedic, dental, and maxillofacial surgery. These are Class III medical devices based on implantable natural polysaccharides that stimulate bone growth. The company was founded as a spin-off from research at Inserm and Bordeaux University and holds exclusive rights to four Inserm patents. Products are pending CE marking prior to commercialization.

Therapeutic areas: RheumatologyOther
Modalities: Biomaterial-based therapyMedical device (natural-origin biomaterials containing implantable natural polysaccharides)
Industry: Implantable Medical Devices

Partnerships

Inserm/Inserm Transfert – exclusive license agreement for core technology

Beyond the preview

Go deeper on SILTISS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SILTISS.

Explore the full profile